Biblioteca Virtual em Saúde

Pesquisa | Influenza A (H1N1)

  • BIREME | OPAS | OMS logo
 

Histórico de pesquisa  ()

Sua seleção  ()

 0 documento(s) selecionado(s).

Enviar por email

Você tem 0 documento(s) selecionado(s).

Nenhum documento selecionado

 
Resultados  1-12 de 39
1.

Genetic Characterization of Circulating 2015 A(H1N1)pdm09 Influenza Viruses from Eastern India.

Autor(es): Mukherjee, Anupam; Nayak, Mukti Kant; Dutta, Shanta; Panda, Samiran; Satpathi, Biswa Ranjan; Chawla-Sarkar, Mamta
Fonte: PLoS One;11(12): e0168464, 2016.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27997573
Resumo: In 2015, the swine derived A(H1N1)pdm09 pandemic strain outbreak became widespread throughout the different states of India. The reported cases and deaths in 2015 surpassed the previous years with more than 39000 laboratory confirmed cases and a death toll of more than 2500 people. There are relatively limited complete genetic sequences available for this virus from Asian countries. In this study, we describe the full genome analysis of influenza 2015 A(H1N1)pdm09 viruses isolated from West (mais)
2.

Update: Influenza Activity - United States, October 2-December 17, 2016.

Autor(es): Shang, Mei; Blanton, Lenee; Kniss, Krista; Mustaquim, Desiree; Alabi, Noreen; Barnes, Stephen; Budd, Alicia; Davlin, Stacy L; Kramer, Natalie; Garg, Shikha; Cummings, Charisse N; Flannery, Brendan; Fry, Alicia M; Grohskopf, Lisa A; Olsen, Sonja J; Bresee, Joseph; Sessions, Wendy; Garten, Rebecca; Xu, Xiyan; Elal, Anwar Isa Abd; Gubareva, Larisa; Barnes, John; Wentworth, David E; Burns, Erin; Katz, Jacqueline; Jernigan, Daniel; Brammer, Lynnette
Fonte: MMWR Morb Mortal Wkly Rep;65(5051): 1439-1444, 2016 Dec 30.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 28033315
Resumo: This report summarizes U.S. influenza activity during October 2-December 17, 2016. Influenza activity in the United States remained low in October and has been slowly increasing since November. Influenza A viruses were identified most frequently, with influenza A (H3N2) viruses predominating. Most influenza viruses characterized during this period were genetically or antigenically similar to the reference viruses representing vaccine components recommended for production in the 2016-17 Northern Hemisphere influenza vaccines.
4.

An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy.

Autor(es): Bank, Claudia; Renzette, Nicholas; Liu, Ping; Matuszewski, Sebastian; Shim, Hyunjin; Foll, Matthieu; Bolon, Daniel N A; Zeldovich, Konstantin B; Kowalik, Timothy F; Finberg, Robert W; Wang, Jennifer P; Jensen, Jeffrey D
Fonte: Evolution;70(11): 2470-2484, 2016 Nov.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27566611
Resumo: The rapid evolution of drug resistance remains a critical public health concern. The treatment of influenza A virus (IAV) has proven particularly challenging, due to the ability of the virus to develop resistance against current antivirals and vaccines. Here, we evaluate a novel antiviral drug therapy, favipiravir, for which the mechanism of action in IAV involves an interaction with the viral RNA-dependent RNA polymerase resulting in an effective increase in the viral mutation rate. We use (mais)
5.

A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro.

Autor(es): Jones, Jeremy C; Marathe, Bindumadhav M; Lerner, Christian; Kreis, Lukas; Gasser, Rodolfo; Pascua, Philippe Noriel Q; Najera, Isabel; Govorkova, Elena A
Fonte: Antimicrob Agents Chemother;60(9): 5504-14, 2016 Sep.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27381402
Resumo: Antiviral drugs are important in preventing and controlling influenza, particularly when vaccines are ineffective or unavailable. A single class of antiviral drugs, the neuraminidase inhibitors (NAIs), is recommended for treating influenza. The limited therapeutic options and the potential risk of antiviral resistance are driving the search for additional small-molecule inhibitors that act on influenza virus proteins. The acid polymerase (PA) of influenza viruses is a promising target for n (mais)
6.

Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.

Autor(es): Ma, Chunlong; Zhang, Jiantao; Wang, Jun
Fonte: Mol Pharmacol;90(3): 188-98, 2016 Sep.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27385729
Resumo: Adamantanes (amantadine and rimantadine) are one of the two classes of Food and Drug Administration-approved antiviral drugs used for the prevention and treatment of influenza A virus infections. They inhibit viral replication by blocking the wild-type (WT) M2 proton channel, thus preventing viral uncoating. However, their use was discontinued due to widespread drug resistance. Among a handful of drug-resistant mutants, M2-S31N is the predominant mutation and persists in more than 95% of cu (mais)
7.

Influenza Activity - United States, 2015-16 Season and Composition of the 2016-17 Influenza Vaccine.

Autor(es): Davlin, Stacy L; Blanton, Lenee; Kniss, Krista; Mustaquim, Desiree; Smith, Sophie; Kramer, Natalie; Cohen, Jessica; Cummings, Charisse Nitura; Garg, Shikha; Flannery, Brendan; Fry, Alicia M; Grohskopf, Lisa A; Bresee, Joseph; Wallis, Teresa; Sessions, Wendy; Garten, Rebecca; Xu, Xiyan; Elal, Anwar Isa Abd; Gubareva, Larisa; Barnes, John; Wentworth, David E; Burns, Erin; Katz, Jacqueline; Jernigan, Daniel; Brammer, Lynnette
Fonte: MMWR Morb Mortal Wkly Rep;65(22): 567-75, 2016 Jun 10.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27281364
Resumo: During the 2015-16 influenza season (October 4, 2015-May 21, 2016) in the United States, influenza activity* was lower and peaked later compared with the previous three seasons (2012-13, 2013-14, and 2014-15). Activity remained low from October 2015 until late December 2015 and peaked in mid-March 2016. During the most recent 18 influenza seasons (including this season), only two other seasons have peaked in March (2011-12 and 2005-06). Overall influenza activity was moderate this season, w (mais)
8.

Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016.

Autor(es): Takashita, Emi; Fujisaki, Seiichiro; Shirakura, Masayuki; Nakamura, Kazuya; Kishida, Noriko; Kuwahara, Tomoko; Shimazu, Yukie; Shimomura, Takeshi; Watanabe, Shinji; Odagiri, Takato
Fonte: Euro Surveill;21(24)2016 Jun 16.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27336226
Resumo: An influenza A(H1N1)pdm09 virus carrying a G147R substitution in combination with an H275Y substitution in the neuraminidase protein, which confers cross-resistance to oseltamivir and peramivir, was detected from an immunocompromised inpatient in Japan, March 2016. This dual H275Y/G147R mutant virus exhibited enhanced cross-resistance to both drugs compared with the single H275Y mutant virus and reduced susceptibility to zanamivir, although it showed normal inhibition by laninamivir.
9.

In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors against clinical isolates of the influenza viruses circulating in the 2010-2011 to 2014-2015 Japanese influenza seasons.

Autor(es): Ikematsu, Hideyuki; Kawai, Naoki; Iwaki, Norio; Kashiwagi, Seizaburo
Fonte: J Infect Chemother;22(9): 599-604, 2016 Sep.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27346379
Resumo: To assess the extent of viral resistance to the four neuraminidase inhibitors (NAIs), we measured their 50% inhibitory concentration (IC50) for influenza virus isolates from the 2014-2015 influenza season for comparison with those circulating in the 2010-2011 to 2013-2014 influenza seasons. Viral isolation was done with specimens obtained prior to treatment, and the type and subtype of influenza was determined by RT-PCR using type- and subtype-specific primers. The IC50 was determined by a (mais)
10.

Exploiting Genetic Interference for Antiviral Therapy.

Autor(es): Tanner, Elizabeth J; Kirkegaard, Karla A; Weinberger, Leor S
Fonte: PLoS Genet;12(5): e1005986, 2016 May.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27149616
Resumo: Rapidly evolving viruses are a major threat to human health. Such viruses are often highly pathogenic (e.g., influenza virus, HIV, Ebola virus) and routinely circumvent therapeutic intervention through mutational escape. Error-prone genome replication generates heterogeneous viral populations that rapidly adapt to new selection pressures, leading to resistance that emerges with treatment. However, population heterogeneity bears a cost: when multiple viral variants replicate within a cell, t (mais)
11.

High-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase Activity.

Autor(es): Kurebayashi, Yuuki; Takahashi, Tadanobu; Tamoto, Chihiro; Sahara, Keiji; Otsubo, Tadamune; Yokozawa, Tatsuya; Shibahara, Nona; Wada, Hirohisa; Minami, Akira; Ikeda, Kiyoshi; Suzuki, Takashi
Fonte: PLoS One;11(5): e0156400, 2016.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27232333
Resumo: Influenza A and B viruses possess a neuraminidase protein that shows sialidase activity. Influenza virus-specific neuraminidase inhibitors (NAIs) are commonly used for clinical treatment of influenza. However, some influenza A and B viruses that are resistant to NAIs have emerged in nature. NAI-resistant viruses have been monitored in public hygiene surveys and the mechanism underlying the resistance has been studied. Here, we describe a new assay for selective detection and isolation of an (mais)
12.

A "building block" approach to the new influenza A virus entry inhibitors with reduced cellular toxicities.

Autor(es): Lin, Dongguo; Li, Fangfang; Wu, Qiuyi; Xie, Xiangkun; Wu, Wenjiao; Wu, Jie; Chen, Qing; Liu, Shuwen; He, Jian
Fonte: Sci Rep;6: 22790, 2016 Mar 08.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26952867
Resumo: Influenza A virus (IAV) is a severe worldwide threat to public health and economic development that results in the emergence of drug-resistant or highly virulent strains. Therefore, it is imperative to develop potent anti-IAV drugs with different modes of action to currently available drugs. Herein, we show a new class of antiviral peptides generated by conjugating two known short antiviral peptides: part-1 (named Jp with the sequence of ARLPR) and part-2 (named Hp with the sequence of KKWK (mais)
Resultados  1-12 de 39